JP2011500723A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500723A5 JP2011500723A5 JP2010530143A JP2010530143A JP2011500723A5 JP 2011500723 A5 JP2011500723 A5 JP 2011500723A5 JP 2010530143 A JP2010530143 A JP 2010530143A JP 2010530143 A JP2010530143 A JP 2010530143A JP 2011500723 A5 JP2011500723 A5 JP 2011500723A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- cancer
- tyrosine kinase
- egfr tyrosine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 31
- 229940121647 egfr inhibitor Drugs 0.000 claims 18
- 239000003795 chemical substances by application Substances 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229960001433 erlotinib Drugs 0.000 claims 4
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 229960005395 cetuximab Drugs 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 229960002584 gefitinib Drugs 0.000 claims 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 229960004891 lapatinib Drugs 0.000 claims 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 229950008001 matuzumab Drugs 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 229960001972 panitumumab Drugs 0.000 claims 2
- 239000005461 Canertinib Substances 0.000 claims 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 1
- -1 caneltinib Chemical compound 0.000 claims 1
- 229950002826 canertinib Drugs 0.000 claims 1
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229950008250 zalutumumab Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98143107P | 2007-10-19 | 2007-10-19 | |
| PCT/US2008/080309 WO2009052379A2 (en) | 2007-10-19 | 2008-10-17 | Improved antitumoral treatments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011500723A JP2011500723A (ja) | 2011-01-06 |
| JP2011500723A5 true JP2011500723A5 (https=) | 2011-12-01 |
Family
ID=40568081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010530143A Pending JP2011500723A (ja) | 2007-10-19 | 2008-10-17 | 改善された抗腫瘍治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20100226919A1 (https=) |
| EP (1) | EP2207561A2 (https=) |
| JP (1) | JP2011500723A (https=) |
| KR (1) | KR20100099128A (https=) |
| CN (1) | CN101861159A (https=) |
| AU (1) | AU2008312400A1 (https=) |
| CA (1) | CA2703720A1 (https=) |
| IL (1) | IL205096A0 (https=) |
| MX (1) | MX2010004259A (https=) |
| NZ (1) | NZ584695A (https=) |
| RU (1) | RU2010119922A (https=) |
| WO (1) | WO2009052379A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2252315A1 (en) * | 2008-01-30 | 2010-11-24 | Pharma Mar, S.A. | Improved antitumoral treatments |
| EP2262522A1 (en) * | 2008-03-07 | 2010-12-22 | Pharma Mar, S.A. | Improved antitumoral treatments |
| WO2012103341A1 (en) * | 2011-01-27 | 2012-08-02 | Merrimack Pharmaceuticals, Inc. | Treatment of advanced solid stage tumors using anti-erbb3 antibodies |
| KR102491180B1 (ko) | 2017-04-27 | 2023-01-20 | 파르마 마르 에스.에이. | 항종양 화합물 |
| WO2021148396A1 (en) * | 2020-01-20 | 2021-07-29 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) * | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| CA2082160C (en) * | 1991-03-06 | 2003-05-06 | Mary M. Bendig | Humanised and chimeric monoclonal antibodies |
| GB9300059D0 (en) * | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| GB9302046D0 (en) * | 1993-02-03 | 1993-03-24 | Pharma Mar Sa | Antiumoral compound-v |
| US6274551B1 (en) * | 1994-02-03 | 2001-08-14 | Pharmamar, S.A. | Cytotoxic and antiviral compound |
| US5705511A (en) * | 1994-10-14 | 1998-01-06 | Cephalon, Inc. | Fused pyrrolocarbazoles |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| AR007857A1 (es) * | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
| AU7476198A (en) * | 1997-05-09 | 1998-11-27 | General Hospital Corporation, The | Cell proliferation related genes |
| JP3948501B2 (ja) * | 1997-08-07 | 2007-07-25 | Ｎｓｋワーナー株式会社 | ブレーキドラム |
| RS49779B (sr) * | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| US6200598B1 (en) * | 1998-06-18 | 2001-03-13 | Duke University | Temperature-sensitive liposomal formulation |
| EA003786B1 (ru) * | 1998-11-19 | 2003-10-30 | Варнер Ламберт Компани | N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ |
| US7311924B2 (en) * | 1999-04-01 | 2007-12-25 | Hana Biosciences, Inc. | Compositions and methods for treating cancer |
| UA74803C2 (uk) * | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
| GB0002952D0 (en) * | 2000-02-09 | 2000-03-29 | Pharma Mar Sa | Process for producing kahalalide F compounds |
| NZ525243A (en) * | 2000-10-31 | 2005-01-28 | Pharma Mar S | A lyophilised formulation comprising kahalalide F, a peptide isolated from a herbivorous marine species of mollusc, Elysia rufescens, to treat cancer |
| US20050054555A1 (en) * | 2001-10-19 | 2005-03-10 | Jose Jimeno | Kahalalide compounds for use in cancer therapy |
| EP1572726B1 (en) * | 2002-10-18 | 2010-12-08 | Pharma Mar, S.A.U. | 4-methylhexanoic kahalalide f compound |
| GB0304367D0 (en) * | 2003-02-26 | 2003-04-02 | Pharma Mar Sau | Methods for treating psoriasis |
| US7507708B2 (en) * | 2003-02-26 | 2009-03-24 | Pharma Mar, S.A.U. | Antitumoral compounds |
| GB0321066D0 (en) * | 2003-09-09 | 2003-10-08 | Pharma Mar Sau | New antitumoral compounds |
| GB0408958D0 (en) * | 2004-04-22 | 2004-05-26 | Pharma Mar Sa | Convergent synthesis for kahalalide compounds |
| AP2008004569A0 (en) * | 2006-02-03 | 2008-08-31 | Imclone Systems Inc | IGR-IR antagonists as adjuvants for treatment of prostrate cancer |
-
2008
- 2008-10-17 WO PCT/US2008/080309 patent/WO2009052379A2/en not_active Ceased
- 2008-10-17 US US12/682,921 patent/US20100226919A1/en not_active Abandoned
- 2008-10-17 CN CN200880116576A patent/CN101861159A/zh active Pending
- 2008-10-17 EP EP08840671A patent/EP2207561A2/en not_active Withdrawn
- 2008-10-17 NZ NZ584695A patent/NZ584695A/en not_active IP Right Cessation
- 2008-10-17 AU AU2008312400A patent/AU2008312400A1/en not_active Abandoned
- 2008-10-17 JP JP2010530143A patent/JP2011500723A/ja active Pending
- 2008-10-17 MX MX2010004259A patent/MX2010004259A/es unknown
- 2008-10-17 CA CA2703720A patent/CA2703720A1/en not_active Abandoned
- 2008-10-17 KR KR1020107011020A patent/KR20100099128A/ko not_active Withdrawn
- 2008-10-17 RU RU2010119922/15A patent/RU2010119922A/ru not_active Application Discontinuation
-
2010
- 2010-04-14 IL IL205096A patent/IL205096A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010516770A5 (https=) | ||
| CN103533961B (zh) | 以表皮生长因子受体为靶向的治疗癌症的组合方法 | |
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| RU2009132674A (ru) | Комбинированная терапия с использованием ингибиторов ангиогенеза | |
| GEP20115147B (en) | Pyrimidine derivatives used as pi-3 kinase inhibitors | |
| RU2016122654A (ru) | Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка | |
| JP2012082234A5 (https=) | ||
| RU2013131004A (ru) | Комбинация (а) ингибитора фосфоинозит-3-киназы и (б) модулятора пути ras/raf/mek | |
| MY202114A (en) | Treatment of brain cancer | |
| JP2016528251A5 (https=) | ||
| EA200970932A1 (ru) | Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа | |
| IL184791A (en) | Gaffitinib-Resistant Cancer Treatment Compounds A method to treat gafitinib-resistant cancer with an EGFR gene t790m using irreversible EGFR inhibitors | |
| EA201200560A1 (ru) | Специфическая терапия, использующая интегриновые лиганды для лечения рака | |
| JP2016535756A5 (https=) | ||
| WO2008024439A3 (en) | 4-aminoquinazoline derivatives and methods of use thereof | |
| NO20060398L (no) | Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft | |
| RU2020142739A (ru) | Ингибиторы mdm2 и их комбинации | |
| RU2014128513A (ru) | Раковый маркер и терапевтическая мишень | |
| RU2014144254A (ru) | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение | |
| JP2017536408A5 (https=) | ||
| RU2013132018A (ru) | Применение производных пиримидина для лечения egfr-зависимых заболеваний или заболеваний с приобретенной резистентностью к агентам, направленным против членов семейства egfr | |
| BRPI0908635B8 (pt) | composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica | |
| JP2011500723A5 (https=) | ||
| RU2018138626A (ru) | Комбинированная терапия ингибиторами notch и pi3k/mtor для применения в лечении рака | |
| PH12016502353A1 (en) | Pharmaceutical composition |